DelveInsight has released its latest report, “Chronic Pain Market Insights, Epidemiology and Market Forecast – 2034,” delivering an in-depth analysis of the evolving chronic pain treatment landscape. The report offers a comprehensive overview of the epidemiology, drug uptake, treatment algorithms, competitive intelligence, and market dynamics shaping the outlook of chronic pain therapies across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
To know more about the Chronic Pain market outlook, drug uptake, treatment scenario, and epidemiology trends, Click Here: Chronic Pain Market Forecast
Key Highlights from DelveInsight’s Chronic Pain Market Report
- The Chronic Pain Market Size is anticipated to witness a substantial positive shift owing to better uptake of existing drugs, the expected market launch of therapies, and raised awareness during the forecast period (2020-2034).
- In March 2025, NeuroOne Medical Technologies announced it has expedited its 510(k) submission timeline to the U.S. Food and Drug Administration (FDA) for trigeminal nerve ablation, now set for May 2025. The technology utilizes the company’s OneRF platform.
- In February 2025, BioRestorative Therapies announced that the FDA cleared its Investigational New Drug (IND) application for BRTX-100, a novel cell-based therapeutic for treating chronic cervical discogenic pain (cCDP) by targeting areas with little blood flow.
- In January 2025, Zynex Inc. expanded its portfolio of non-invasive medical devices for pain management and rehabilitation. The FDA recently cleared Zynex’s TensWave device, which uses Transcutaneous Electrical Nerve Stimulation (TENS) therapy for portable, drug-free pain relief.
- Key chronic pain therapies include EMGALITY (galcanezumab-gnlm), TARLIGE (mirogabalin besylate), AIMOVIG (erenumab-aooe), AJOVY (fremanezumab), VYEPTI (eptinezumab), PENNSAID Gel, JOYCLU (diclofenac etalhyaluronate sodium), and ZILRETTA (triamcinolone acetonide extended-release injectable suspension).
- Emerging pipeline candidates include ZILOSUL (pentosan polysulfate sodium) by Paradigm Biopharmaceuticals, CNTX-4975-05 by Centrexion Therapeutics, and TNX-102 SL by Tonix Pharmaceuticals.
- Pharmaceutical companies driving chronic pain treatment innovation include Seikagaku Corporation, Chiltern International Inc., Pacira BioSciences, Paradigm Biopharmaceuticals, Centrexion Therapeutics, Tonix Pharmaceuticals, and others.
- In 2023, among the 7MM countries, the US accounted for the most number of total Chronic Pain Prevalent Cases followed by Japan and the UK.
- The United States accounts for the largest Chronic Pain Market Size, in comparison to EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
- Among the EU4 and the UK, the United Kingdom accounted for the highest Chronic Pain Market Size at approximately 29%, followed by Germany in 2023.
- Rising awareness, alternative options to addictive opioids, holistic approaches, and an aging population are set to transform market dynamics.
- Opioids have been the mainstay of treatment for patients experiencing moderate to severe pain, with around 168 million prescriptions written for opioids in 2018 in the US.
Learn more about Chronic Pain treatment algorithms in different geographies and patient journeys. Contact to receive a sample @ Chronic Pain Treatment Market
Chronic Pain: Disease Understanding and Clinical Context
The International Association for the Study of Pain (IASP) defines pain as an unpleasant sensory and emotional experience linked to actual or potential tissue damage. Chronic pain persists for extended periods (>3 months) and often requires ongoing treatment, ranging from mild to severe intensity.
Chronic pain can stem from injury or the brain’s mishandling of pain signals. Common sources include low back pain, musculoskeletal pain, migraines, fibromyalgia, neuralgia, cancer pain, visceral pain, and post-operative pain, though many causes remain unidentified.
Continuous acute pain can lead to sensitization, where pain pathways undergo structural and functional changes in the peripheral or central nervous system. This results in a lower pain threshold, heightened excitability, and increased responsiveness to pain, ultimately transitioning acute pain into chronic pain.
Chronic pain diagnosis typically occurs after 3–6 months of persistent pain. Tests depend on pain location, cause, and accompanying symptoms, including blood tests, imaging studies (X-rays, MRIs for soft tissues and inflammation, CT scans for detailed examination), and nerve testing.
Combination therapy for pain includes pharmacological as well as non-pharmacological treatment options. There is greater pain reduction with combination therapy compared to single treatment approaches. Comorbid depression and anxiety are widespread in chronic pain patients, who are at an increased risk of suicide. Chronic pain can impact every facet of a patient’s life, making diagnosis and appropriate management critical.
Epidemiology Insights for Chronic Pain
DelveInsight’s epidemiology analysis evaluates the diagnosed and prevalent patient population across the 7MM from 2020 to 2034. The study segments data by prevalence, age distribution, disease causes, severity status, and treatment patterns.
- Overall Prevalence: In 2023, the total 7MM Chronic Pain Prevalent Cases showed the US accounted for the highest number of cases.
- Regional Distribution: Among the EU4 and the UK, the highest number of Chronic Pain prevalent cases were observed in the UK at approximately 30%.
- Age-Specific Trends: Prevalence of chronic pain increased with age and was higher among those in the age group between 45-64 years.
- Severity Stratification: Approximately 70% of chronic pain cases in the United States in 2023 fall within the category of moderate to severe severity-specific cases.
- Treatment Patterns: The diagnosed patient pool reflects significant opportunities for therapeutic intervention across varying severity levels.
Explore more about Chronic Pain Epidemiology @ Chronic Pain Market Dynamics
Drug Uptake and Pipeline Advancements
The chronic pain treatment landscape encompasses both established marketed therapies and emerging pipeline candidates progressing through late-stage clinical development.
Current Treatment Landscape:
Marketed Therapies:
- JOYCLU (diclofenac etalhyaluronate sodium) – Seikagaku Corporation/Chiltern International: A formulation in which hyaluronic acid and diclofenac are chemically bound using proprietary technology, designed to release diclofenac by hydrolysis in the joint for osteoarthritis treatment.
- ZILRETTA (triamcinolone acetonide extended-release injectable suspension) – Pacira BioSciences: An intra-articular injection to manage osteoarthritis pain in the knee, approved by the FDA in October 2017.
- EMGALITY (galcanezumab-gnlm): Approved therapy for chronic pain management
- AIMOVIG (erenumab-aooe): Targeted treatment option
- AJOVY (fremanezumab): Established therapeutic intervention
- VYEPTI (eptinezumab): Modern pain management solution
- TARLIGE (mirogabalin besylate): Alternative treatment approach
- PENNSAID Gel: Topical pain relief option
Emerging Pipeline Assets:
- ZILOSUL (Pentosan Polysulfate Sodium) – Paradigm Biopharmaceuticals: Phase III candidate with Fast Track Designation (FDA). Subcutaneous administration acting as a non-nucleoside reverse transcriptase inhibitor with anti-inflammatory and tissue regenerative properties.
- CNTX-4975-05 – Centrexion Therapeutics: Phase III candidate with Fast Track Designation (FDA). Intra-articular TRPV1 receptor agonist for pain management.
- TNX-102 SL – Tonix Pharmaceuticals: Phase III sublingual tablet containing 2.8 mg of cyclobenzaprine HCl for fibromyalgia treatment. Acts as an alpha 1 adrenergic receptor antagonist with centrally-acting analgesic properties.
Several of these agents are anticipated to enter the market during the forecast period, potentially reshaping treatment paradigms and competitive dynamics.
Chronic Pain Market Drivers and Challenges
Chronic Pain Market Drivers
- Rising chronic pain prevalence and increasing awareness about treatment options
- Growing need for alternatives to addictive opioids amid the opioid crisis
- Expansion of holistic and multimodal treatment approaches combining pharmacological and non-pharmacological interventions
- Upsurge in the geriatric population with age-related chronic pain conditions
- Better uptake of existing drugs and improved patient access to treatment
- Development of novel therapeutic agents targeting specific pain mechanisms
- Integration of exercise, physical therapy, counseling, electrical stimulation, biofeedback, acupuncture, and other complementary treatments
- Organizational efforts to improve pain management standards and guidelines
Chronic Pain Market Barriers
- Challenging diagnosis and difficulties in identifying specific pain biomarkers
- Significant impact of chronic pain on patients’ quality of life affecting treatment adherence
- Opioids misuse and addiction concerns limiting prescribing practices
- Economic burden associated with chronic pain management
- Limited availability of truly disease-modifying therapies
- Variable treatment response across different patient populations
- Regulatory challenges for novel pain management therapies
- Reimbursement complexities for multimodal treatment approaches
Chronic Pain Competitive Landscape
The chronic pain treatment market features both established pharmaceutical companies and emerging biotech innovators developing novel therapeutic approaches.
Key Chronic Pain Companies:
- Seikagaku Corporation/Chiltern International Inc. – JOYCLU
- Pacira BioSciences – ZILRETTA
- Paradigm Biopharmaceuticals – ZILOSUL
- Centrexion Therapeutics – CNTX-4975-05
- Tonix Pharmaceuticals – TNX-102 SL
- NeuroOne Medical Technologies – Trigeminal nerve ablation technology
- BioRestorative Therapies – BRTX-100
- Zynex Inc. – TensWave and NexWave devices
- Additional companies developing targeted therapeutics
These organizations are actively pursuing clinical development programs, regulatory submissions, strategic collaborations, and technological innovations to strengthen their market positioning in the pain management space.
Scope of the Chronic Pain Market Report
DelveInsight’s Chronic Pain Market Insights, Epidemiology and Market Forecast – 2034 includes:
- Study Period: 2020-2034
- Forecast Period: 2024-2034
- Geographic Coverage: 7MM (U.S., EU4, UK, Japan)
- Therapeutic Assessment: Marketed and emerging chronic pain therapies
- Market Dynamics: Comprehensive evaluation of growth drivers, barriers, and competitive insights
- Analytical Frameworks: SWOT analysis, Conjoint analysis, and market intelligence evaluation
- Expert Perspectives: Key opinion leader (KOL) insights on treatment patterns, therapy switching, and market trends
- Epidemiology Analysis: Total Prevalent Cases, Diagnosed Cases, Age-specific Cases, Cause-specific Cases, Severity-specific Cases, and Treated Cases
- Drug Profiles: Detailed analysis of marketed drugs and pipeline therapies including mechanism of action, clinical trial details, regulatory milestones, and competitive positioning
- Real-World Prescription Patterns: Analysis of current treatment practices and prescribing behaviors
- Market Access and Reimbursement: Assessment of accessibility, cost-effectiveness, and reimbursement scenarios
- Treatment Algorithms: Country-specific treatment guidelines and clinical pathways
- Patient Journey: Detailed understanding of patient treatment preferences and therapy switching patterns
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm exclusively focused on life sciences. We empower pharmaceutical and biotech companies with robust, end-to-end solutions for enhancing strategic decision-making and performance. Our Healthcare Consulting Services leverage market intelligence to drive growth and resolve challenges with an actionable, practical approach.
Contact Information
Kanishk
